New hope for Tough-to-Treat lymphoma: experimental combo enters Mid-Stage trial
NCT ID NCT05800366
Summary
This study is testing whether adding two newer drugs, glofitamab and polatuzumab, to a standard chemotherapy regimen (R-CHP) works better for people with newly diagnosed, high-risk diffuse large B-cell lymphoma. About 40 participants will receive the drug combination for up to 8 cycles and be followed for 5 years to see if the treatment effectively controls the cancer and is safe. The main goal is to see how many patients achieve a complete disappearance of their cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beth Israel Deaconess Medical Center
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Email: •••••@•••••
Contact
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Email: •••••@•••••
Contact
Contact
-
University of Miami Sylvester Cancer Center
RECRUITINGMiami, Florida, 33136, United States
Contact
Conditions
Explore the condition pages connected to this study.